Loading stock data…
Nuvalent, Inc. (NUVL)
$123.96
Market Closed
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$119.41M↓ | -$102.23M↑ | -$112.70M↓ | -$104.57M↓ | -$94.81M |
| Net Income | -$109.28M↑ | -$118.70M↑ | -$122.44M↓ | -$99.65M↓ | -$84.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.32%
Volume
Today's trading volume
3.09M
Recent News
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower
Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach...
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. GSK plc (NYSE:GSK) is one of the best low-priced pharma stocks on this list. TheFly reported on June 24 that GSK announced that Harmony Row Acquisition Co., an indirect wholly owned subsidiary, has formally launched a tender offer to acquire all […]
Candel Therapeutics Designates Mark Sims as CCO
By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.